Home > Journals > Minerva Chirurgica > Past Issues > Minerva Chirurgica 2012 June;67(3) > Minerva Chirurgica 2012 June;67(3):227-34

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CHIRURGICA

A Journal on Surgery


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,115


eTOC

 

ORIGINAL ARTICLES  


Minerva Chirurgica 2012 June;67(3):227-34

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

Pulmonary metastasectomy from head and neck tumors

Younes R. N. 1, Fares A. L. 2, Silva Sardenberg R. A. 3, Gross J. L. 4

1 Department of Surgery, LIM-62, University of São Paulo Medical School Universida de Paulista UNIP, Thoracic Surgeon of Hospital São José, São Paulo, SP, Brasil; 2 Santa Casa de São Paulo Medical School, Faculty of Medical Sciences of Santa Casa de São Paulo – FCMSCSP, São Paulo, SP, Brasil; 3 Thoracic Surgeon, Department of Thoracic Surgery, Hospital Sírio-Libanês and Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brasil; 4 Thoracic Surgeon, Department of Thoracic Surgery, Hospital AC Camargo and Hospital Sírio-Libanês, São Paulo, SP, Brasil


PDF  


AIM:Isolated pulmonary metastases from head and neck cancer occur in 20%-30% of patients affected by head and neck neoplams. Surgical resection is well accepted as a standard approach to treat metastases from head and neck cancer isolated to the lungs. Many studies reported overall five-year survival ranging from 20% to 30%. The aim of this study is to determine demographics and clinical treatment-related variables associated with long-term (60-month) overall survival in patients with lung metastases undergoing pulmonary metastasectomy from head and neck tumors.
METHODS: A retrospective review was performed of patients who were admitted with lung metastases and underwent thoracotomy for resection after treatment of the primary tumor. Data were collected regarding primary tumor features, demographics, treatment, and outcome.
RESULTS: Median follow-up time of all patients was 36.4 months (range: 0-288 months). The postoperative complication rate was 14.4%, and the 30-day mortality rate was 0%. The 60-month overall survival rate for all patients was 35.5%. Multivariate analysis identified the number of nodules at CT scan, the disease-free interval, and histological type as independent prognostic factors for overall survival.
CONCLUSION: Lung metastasectomy is a safe and potentially curative procedure for patients with treated primary tumors. A select group of patients can achieve long-term survival after lung resection.

top of page

Publication History

Cite this article as

Corresponding author e-mail